title: Spinal neurokinin NK1 receptor down-regulation and antinociception: effects of spinal NK1 receptor antisense oligonucleotides and NK1 receptor occupancy.
abstract: To define the effects of antisense oligonucleotides on spinal neurokinin 1 (NK1) receptor function in nociceptive processing, several antisense oligonucleotides directed against the NK1 receptor mRNA were intrathecally injected into rats via an implanted catheter, and their effect on the behavioural response to formalin injected into the paw was assessed. We observed that there was no significant reduction of pain behaviour or immunostaining of spinal NK1 receptors after repeated daily intrathecal treatment with an antisense oligonucleotide. However, spinal application of substance P (SP) in the antisense oligonucleotide-treated animals resulted in a profound and long-lasting reduction in the behavioural response to formalin injection, and a parallel reduction in the NK1 receptor immunoreactivity normally observed in spinal dorsal horn. Intrathecal SP in the control groups, i.e., rats treated with an oligonucleotide containing four mismatched bases, the corresponding sense oligonucleotide, a mixture of the sense and the antisense oligonucleotides, in each case had no effect. The effects of SP were blocked by NK1 receptor antagonists and were not mimicked by NMDA. The mechanism underlying these effects is not clear. It may be due to partial degradation of the internalised receptors, which cannot be replaced by newly synthesised receptors because of the action of the NK1 antisense oligonucleotide.
authors.affiliation: Department of Anaesthesiology, University of California-San Diego, La Jolla, USA.
authors.forename: X Y
authors.initials: XY
authors.lastname: Hua
authors.forename: P
authors.initials: P
authors.lastname: Chen
authors.forename: E
authors.initials: E
authors.lastname: Polgar
authors.forename: I
authors.initials: I
authors.lastname: Nagy
authors.forename: M
authors.initials: M
authors.lastname: Marsala
authors.forename: E
authors.initials: E
authors.lastname: Phillips
authors.forename: L
authors.initials: L
authors.lastname: Wollaston
authors.forename: L
authors.initials: L
authors.lastname: Urban
authors.forename: T L
authors.initials: TL
authors.lastname: Yaksh
authors.forename: M
authors.initials: M
authors.lastname: Webb
mesh_terms: D000818:Animals; D015536:Down-Regulation / Q000187:drug effects; D005557:Formaldehyde; D007211:Indoles / Q000494:pharmacology; D007278:Injections, Spinal; D054833:Isoindoles; D008297:Male; D016202:N-Methylaspartate / Q000008:administration & dosage / Q000494:pharmacology*; D016376:Oligonucleotides, Antisense / Q000494:pharmacology*; D010146:Pain / Q000503:physiopathology*; D017288:Pain Threshold / Q000187:drug effects* / Q000502:physiology; D010880:Piperidines / Q000494:pharmacology; D011812:Quinuclidines / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D018040:Receptors, Neurokinin-1 / Q000096:biosynthesis* / Q000187:drug effects / Q000502:physiology; D013116:Spinal Cord / Q000187:drug effects / Q000502:physiology*; D013373:Substance P / Q000494:pharmacology*
chemical_list: D007211:Indoles; D054833:Isoindoles; D016376:Oligonucleotides, Antisense; D010880:Piperidines; D011812:Quinuclidines; D018040:Receptors, Neurokinin-1; C071693:7,7-diphenyl-2-(1-imino-2-(2-methoxyphenyl)ethyl)perhydroisoindol-4-one; C085215:SR 140333; D005557:Formaldehyde; D013373:Substance P; D016202:N-Methylaspartate